Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Newly Discovered Marker Detects Early Pancreatic Cancer

By LabMedica International staff writers
Posted on 16 Oct 2014
A marker in the blood that may indicate early development of the pancreatic ductal adenocarcinoma (PDAC) could pave the way for an early detection test.

Pancreatic cancer is difficult to diagnose early as the tumors cannot be felt like they can in some other cancers because the pancreas is so deep inside the body and the disease usually does not cause any symptoms until it has already spread to other organs.

Scientists at the Dana-Farber Cancer Institute (Boston, MA, USA) assessed previously collected blood samples from 1,500 people who were part of large health-monitoring studies. More...
They looked for more than 100 compounds made during the metabolic process, known as metabolites, before dividing the samples into two groups: those that were from participants who later developed pancreatic cancer and those that were from participants who did not develop the disease.

Profiles of endogenous polar metabolites were obtained using liquid chromatography-tandem mass spectrometry (LC-MS) which consisted of a 4000 QTRAP triple quadrupole mass spectrometer (AB SCIEX; Framingham, USA) coupled to an 1100 Series pump (Agilent Technologies; Santa Clara, CA, USA) and an HTS PAL autosampler (CTC; Zwingen, Switzerland).

The team found that the participants who went on to develop pancreatic cancer had higher blood levels of branched-chain amino acids (BCAAs), which are essential nutrients that the body extracts from proteins found in foods, compared with participants who did not develop pancreatic cancer. The elevated plasma levels of BCAAs were associated with a greater than two-fold increased risk of future pancreatic cancer diagnosis. This elevated risk was independent of known predisposing factors, with the strongest association observed among subjects with samples collected two to five years before diagnosis, when occult disease is probably present.

The authors concluded that these increased BCAA levels were found in patients 2 to 25 years before they were diagnosed with pancreatic cancer, but they note that patients with high levels of these amino acids several years prior to diagnosis were at the highest risk. Matthew G.Vander Heiden, MD, PhD, co-senior author of the study said, “This work has the potential to spur progress in detecting pancreatic tumors earlier and identifying new treatment strategies for those with the disease.” The study was published on September 28, 2014, in the journal Nature Medicine.

Related Links:

Dana-Farber Cancer Institute 
AB SCIEX 
Agilent Technologies 




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.